Development of next generation drugs for chronic myeloid leukaemia

开发下一代治疗慢性粒细胞白血病的药物

• 批准号: nhmrc : 1060225
• 负责人: Dr Quentin Kaas
• 金额: $ 42.19万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-generation-drugs-myeloid-leukaemia/454810
• 关键词: Development; next; generation; drugs; chronic

Chronic myeloid leukaemia (CML) is one of the four most common types of leukaemia. With current therapies, 15–20% of patients newly diagnosed for CML will die in the next five years, and it is therefore vitally important to discover new treatments. The aim of this project is to develop a new generation of drugs to treat CML based on new approaches (i.e., different type of molecules and different binding site) that can combat the resistance acquired to the current treatments.

慢性粒细胞白血病（CML）是四种最常见的白血病类型之一。根据目前的治疗方法，新诊断的 CML 患者中 15-20% 将在未来五年内死亡，因此发现新的治疗方法至关重要。该项目的目的是基于新方法（即不同类型的分子和不同的结合位点）开发新一代治疗 CML 的药物，这些药物可以对抗对当前治疗产生的耐药性。